Amarin Inc. (NASDAQ: AMRN) just went off the charts, literally. The company reported very solid Phase III study results this morning and the stock is now up almost tenfold from its lows…
Jon C. Ogg 2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009. In 2009, companies like Jazz Pharmaceuticals,…
Amarin Corporation plc (NASDAQ: AMRN) is indicated up 50% at $5.35, well above the $3.85 52-week high, after its AMR101 met pivotal phase 3 study endpoints with highly statistically significant reductions in…
